NCT06592417 is a Phase 1 clinical trial of JSKN016 injection in Advanced Malignant Solid Tumor, sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd.

Who is sponsoring NCT06592417?

NCT06592417 is sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd.

What drugs are being tested in NCT06592417?

Interventions in NCT06592417: JSKN016 injection.

What condition does NCT06592417 study?

NCT06592417 studies Advanced Malignant Solid Tumor.

Is NCT06592417 still recruiting?

NCT06592417 is currently recruiting now. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT06592417

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors

Recruiting now Phase 1 Last updated 19 September 2024

What this trial tests

Phase 1 trial testing JSKN016 injection in Advanced Malignant Solid Tumor in 140 participants. Currently enrolling.

Timeline

30 April 2024

Primary endpoint
17 May 2026

31 December 2026

Quick facts

Lead sponsor	Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	140
Start date	30 April 2024
Primary completion	17 May 2026
Estimated completion	31 December 2026
Sites	2 locations across China

Drugs / interventions tested

JSKN016 injection — full drug profile →

Conditions studied

Advanced Malignant Solid Tumor — all drugs for Advanced Malignant Solid Tumor →

Sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd — full company profile →

Who can join

18 and older, any sex, with Advanced Malignant Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase I open, multi-center, first-in-human study evaluating JSKN016 in subjects with advanced metastatic solid tumors, divided into dose escalation and dose extension.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Technical, preclinical, and clinical developments of Fc-glycan-specific antibody-drug conjugates.
Yang Q, Liu Y. · · 2025 · cited 13× · PMID 39568595 · DOI 10.1039/d4md00637b
Antibody-drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives.
Valle I, Grinda T, Antonuzzo L, Pistilli B. · · 2025 · cited 3× · PMID 41022825 · DOI 10.1038/s41523-025-00829-5
Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies.
Zhou K, Liu X, Zhu H. · · 2025 · cited 2× · PMID 41185045 · DOI 10.1186/s13045-025-01752-9
Recent advances in bispecific antibody-drug conjugates for breast cancer therapy.
Ji X, Yang Y, Ma C, Huang W, et al · · 2026 · cited 1× · PMID 41579215 · DOI 10.1007/s00280-025-04863-9
Evolution of bispecific and multispecific antibodies in cancer therapy.
Fontana E, Grochot R, Kotecki N, Doger B, et al · · 2026 · PMID 42099877 · DOI 10.1016/j.lanepe.2026.101599
Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer.
Chow R, Zhang D, Kannout S, Ma A, et al · · 2026 · PMID 42068413 · DOI 10.1007/s00520-026-10674-2

Verify or expand the search:

Other recruiting trials for Advanced Malignant Solid Tumor

Currently open trials in the same condition.

NCT07293754 — An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07050641 — Phase I/II Study of SCTB39-1 in Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
NCT06718946 — Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT05477849 — A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with S · Phase 1 · recruiting
NCT04165590 — Plasmodium Immunotherapy for Advanced Malignant Solid Tumors · Phase 1, PHASE2 · recruiting

Other Jiangsu Alphamab Biopharmaceuticals Co., Ltd trials

Trials by the same sponsor.

NCT07533123 — A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H · Phase 3 · recruiting
NCT07391644 — A Study of JSKN027 in Patients With Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07475559 — JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors · Phase 1 · not yet recruiting
NCT07283198 — A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients Wit · Phase 2 · not yet recruiting
NCT07292402 — JSKN022 in Subjects With Advanced Malignant Solid Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06592417 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06592417.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing